GLP-1 receptor agonists combined with progestin therapy significantly reduce endometrial cancer risk in women with uterine hyperplasia, according to a JAMA Network Open study. A separate meta-analysis finds patients regain 60% of weight lost one year after stopping GLP-1 RAs, with weight regain plateauing at 75.3% of treatment loss.
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07436793 |
Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial |
RECRUITING | PHASE2 |
| NCT06904274 |
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months |
WITHDRAWN | PHASE3 |
